What is Atlas Genetics?
Atlas Genetics operates at the intersection of biotechnology and clinical diagnostics, focusing on the development of point-of-care molecular testing solutions. By prioritizing rapid, accurate, and accessible diagnostic tools, the company addresses critical gaps in infectious disease management and sexual health services. Their technological approach is designed to integrate seamlessly into existing healthcare workflows, enabling providers to deliver immediate results and improve patient outcomes through timely intervention. As a key player in the diagnostic sector, Atlas Genetics leverages advanced molecular science to break down traditional barriers to care, positioning itself as a vital partner for healthcare facilities seeking to modernize their diagnostic capabilities.
How much funding has Atlas Genetics raised?
Atlas Genetics has raised a total of $85.9M across 4 funding rounds:
Series A
$2.5M
Series B
$28.4M
Series C
$20M
Series D
$35M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2014): $28.4M led by Consort Medical - UK, BB Biotech Ventures, YFM Equity Partners, Life Sciences Partners, Novartis, and Johnson & Johnson Development Corporation
Series C (2015): $20M supported by Consort Medical - UK, RMI Partners, Johnson & Johnson Services Inc, BB Biotech Ventures, RusnanoMedInvest, Novartis, and Life Sciences Partners
Series D (2017): $35M featuring RMI Partners, Johnson & Johnson Services Inc, Consort Medical - UK, BB Biotech Ventures, Wondfo Biotech, Technology Venture Partners, and Novartis Venture Fund
Key Investors in Atlas Genetics
Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions.
Johnson & Johnson Services Inc
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies, serving healthcare providers and patients worldwide.
BB Biotech Ventures
BB Biotech Ventures is a healthcare-dedicated venture capital firm that invests in private companies developing drugs, medical devices, and healthcare services.
What's next for Atlas Genetics?
With the successful closure of its latest financing round, Atlas Genetics is well-positioned to execute its next phase of strategic growth. The company is expected to focus on the commercial scaling of its diagnostic platforms, further penetrating international markets and enhancing its product pipeline. By leveraging the expertise and resources of its high-profile investor base, the firm aims to solidify its market leadership in point-of-care testing. Future initiatives will likely center on operational efficiency, the expansion of clinical partnerships, and the continued refinement of its molecular diagnostic technologies to meet the evolving demands of global healthcare systems.
See full Atlas Genetics company page
